iferanserin
Small moleculeexperimental
Iferanserin is a drug which acts as a selective 5-HT2A receptor antagonist. It is under development as an intra-rectal formulation for the treatment of hemorrhoid disease, and as of February 2012, is in phase IIb clinical trials. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Sep 1, 2001 (NCT01483833)
Timeline
Indications
Studied for
Mechanism of action
- Serotonin 2a (5-HT2a) receptorANTAGONIST
HTR2A antagonist
Phase 3 study terminated, primary endpoint was not met on the double blind data (NCT01355874)
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCCC[C@H]1CCc1ccccc1NC(=O)/C=C/c1ccccc1- Mol. weight
- 348.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989686 ↗
- WikipediaIferanserin ↗
- ChEMBLCHEMBL2107754 ↗
Also known as
- iferanserin
- iferanserin
- iferanserin
- iferanserin
- ven-309
- ven-309
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01355874 | Phase 3 | Jul 1, 2011 | University of Rochester, Ventrus Biosciences, Inc |
| NCT01483833 | Phase 2 | Sep 1, 2001 | Ventrus Biosciences, Inc |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ventrus Biosciences, Inc | For profit | 2 | 2 | 2 | 2001 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1